183 related articles for article (PubMed ID: 21324356)
1. A new respirable form of rifampicin.
Son YJ; McConville JT
Eur J Pharm Biopharm; 2011 Aug; 78(3):366-76. PubMed ID: 21324356
[TBL] [Abstract][Full Text] [Related]
2. Preparation of sustained release rifampicin microparticles for inhalation.
Son YJ; McConville JT
J Pharm Pharmacol; 2012 Sep; 64(9):1291-302. PubMed ID: 22881441
[TBL] [Abstract][Full Text] [Related]
3. Development and Evaluation of Chitosan Microparticles Based Dry Powder Inhalation Formulations of Rifampicin and Rifabutin.
Pai RV; Jain RR; Bannalikar AS; Menon MD
J Aerosol Med Pulm Drug Deliv; 2016 Apr; 29(2):179-95. PubMed ID: 26406162
[TBL] [Abstract][Full Text] [Related]
4. Co-spray drying of hygroscopic kanamycin with the hydrophobic drug rifampicin to improve the aerosolization of kanamycin powder for treating respiratory infections.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Sinha S; Das SC
Int J Pharm; 2018 Apr; 541(1-2):26-36. PubMed ID: 29458207
[TBL] [Abstract][Full Text] [Related]
5. Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols.
Park CW; Li X; Vogt FG; Hayes D; Zwischenberger JB; Park ES; Mansour HM
Int J Pharm; 2013 Oct; 455(1-2):374-92. PubMed ID: 23820131
[TBL] [Abstract][Full Text] [Related]
6. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin.
Momin MAM; Tucker IG; Das SC
Drug Dev Ind Pharm; 2019 Jul; 45(7):1205-1213. PubMed ID: 30990097
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Granulated Lactose as a Carrier for Dry Powder Inhaler Formulations 2: Effect of Drugs and Drug Loading.
Du P; Du J; Smyth HDC
J Pharm Sci; 2017 Jan; 106(1):366-376. PubMed ID: 27939234
[TBL] [Abstract][Full Text] [Related]
8. Effects of the antibiotic component on in-vitro bacterial killing, physico-chemical properties, aerosolization and dissolution of a ternary-combinational inhalation powder formulation of antibiotics for pan-drug resistant Gram-negative lung infections.
Mangal S; Huang J; Shetty N; Park H; Lin YW; Yu HH; Zemlyanov D; Velkov T; Li J; Zhou QT
Int J Pharm; 2019 Apr; 561():102-113. PubMed ID: 30797863
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of highly branched cyclic dextrin in inhalable particles of combined antibiotics for the pulmonary delivery of anti-tuberculosis drugs.
Kadota K; Senda A; Tagishi H; Ayorinde JO; Tozuka Y
Int J Pharm; 2017 Jan; 517(1-2):8-18. PubMed ID: 27913241
[TBL] [Abstract][Full Text] [Related]
10. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
Li X; Vogt FG; Hayes D; Mansour HM
Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
[TBL] [Abstract][Full Text] [Related]
11. A novel dry powder inhalable formulation incorporating three first-line anti-tubercular antibiotics.
Chan JG; Chan HK; Prestidge CA; Denman JA; Young PM; Traini D
Eur J Pharm Biopharm; 2013 Feb; 83(2):285-92. PubMed ID: 22982733
[TBL] [Abstract][Full Text] [Related]
12. Development of porous particles using dextran as an excipient for enhanced deep lung delivery of rifampicin.
Kadota K; Yanagawa Y; Tachikawa T; Deki Y; Uchiyama H; Shirakawa Y; Tozuka Y
Int J Pharm; 2019 Jan; 555():280-290. PubMed ID: 30471373
[TBL] [Abstract][Full Text] [Related]
13. A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment.
Khadka P; Hill PC; Zhang B; Katare R; Dummer J; Das SC
Int J Pharm; 2020 Sep; 587():119602. PubMed ID: 32663580
[TBL] [Abstract][Full Text] [Related]
14. Particle engineering of materials for oral inhalation by dry powder inhalers. II-Sodium cromoglicate.
Nolan LM; Li J; Tajber L; Corrigan OI; Healy AM
Int J Pharm; 2011 Feb; 405(1-2):36-46. PubMed ID: 21129460
[TBL] [Abstract][Full Text] [Related]
15. Manipulation of spray-drying conditions to develop dry powder particles with surfaces enriched in hydrophobic material to achieve high aerosolization of a hygroscopic drug.
Momin MAM; Tucker IG; Doyle CS; Denman JA; Das SC
Int J Pharm; 2018 May; 543(1-2):318-327. PubMed ID: 29626509
[TBL] [Abstract][Full Text] [Related]
16. Potential of aerosolized rifampicin lipospheres for modulation of pulmonary pharmacokinetics and bio-distribution.
Singh C; Koduri LV; Dhawale V; Bhatt TD; Kumar R; Grover V; Tikoo K; Suresh S
Int J Pharm; 2015 Nov; 495(2):627-32. PubMed ID: 26392246
[TBL] [Abstract][Full Text] [Related]
17. Dry powder inhalers of gentamicin and leucine: formulation parameters, aerosol performance and in vitro toxicity on CuFi1 cells.
Aquino RP; Prota L; Auriemma G; Santoro A; Mencherini T; Colombo G; Russo P
Int J Pharm; 2012 Apr; 426(1-2):100-107. PubMed ID: 22301426
[TBL] [Abstract][Full Text] [Related]
18. Phospholipid-based pyrazinamide spray-dried inhalable powders for treating tuberculosis.
Eedara BB; Tucker IG; Das SC
Int J Pharm; 2016 Jun; 506(1-2):174-83. PubMed ID: 27091294
[TBL] [Abstract][Full Text] [Related]
19. [Design of Spray-dried Porous Particles for Sugar-based Dry Powder Inhaler Formulation].
Kadota K
Yakugaku Zasshi; 2018; 138(9):1163-1167. PubMed ID: 30175760
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Vandenheuvel D; Singh A; Vandersteegen K; Klumpp J; Lavigne R; Van den Mooter G
Eur J Pharm Biopharm; 2013 Aug; 84(3):578-82. PubMed ID: 23353012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
